Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01386996
Recruitment Status : Completed
First Posted : July 1, 2011
Last Update Posted : December 22, 2011
Sponsor:
Information provided by (Responsible Party):
Orion Corporation, Orion Pharma

Brief Summary:
The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbuhaler in terms of the drug absorbed into the bloodstream.

Condition or disease Intervention/treatment Phase
Asthma Drug: Budesonide/formoterol Easyhaler 320/9 microg Drug: Symbicort Turbuhaler forte Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pharmacokinetic Study Comparing Two Budesonide/Formoterol Fumarate Dihydrate Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler 320/9 Microg/Inhalation and Symbicort Turbuhaler Forte; a Randomised, Double-blind, Single Centre, Single Dose, Crossover Study in Healthy Subjects
Study Start Date : July 2011
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Charcoal and Budesonide/formoterol Easyhaler Drug: Budesonide/formoterol Easyhaler 320/9 microg
2 inhalations as a single dose

Active Comparator: Charcoal and Symbicort Turbuhaler Drug: Symbicort Turbuhaler forte
2 inhalations as a single dose

Experimental: Budesonide/formoterol Easyhaler Drug: Budesonide/formoterol Easyhaler 320/9 microg
2 inhalations as a single dose

Active Comparator: Symbicort Turbuhaler Drug: Symbicort Turbuhaler forte
2 inhalations as a single dose




Primary Outcome Measures :
  1. Pharmacokinetic parameter Cmax of plasma budesonide concentration [ Time Frame: within 12 h ]
  2. Pharmacokinetic parameter AUCt of plasma budesonide concentration [ Time Frame: 12 h ]
  3. Pharmacokinetic parameter Cmax of plasma formoterol concentration [ Time Frame: 24 h ]
  4. Pharmacokinetic parameter AUCt of plasma formoterol concentration [ Time Frame: 24 h ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy males and females aged 18-60 years.
  2. Normal weight, at least 50 kg.

Exclusion criteria

  1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease.
  2. Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study.
  3. Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study.
  4. Known hypersensitivity to the active substance(s) or the excipient of the drug.
  5. Pregnant or lactating females.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01386996


Locations
Layout table for location information
Finland
Orion Pharma Phase I Unit
Espoo, Finland
Sponsors and Collaborators
Orion Corporation, Orion Pharma
Investigators
Layout table for investigator information
Study Director: Ulla Sairanen, MSc Orion Corporation, Orion Pharma
Principal Investigator: Kimmo Ingman, MD, PhD Orion Corporation, Orion Pharma

Layout table for additonal information
Responsible Party: Orion Corporation, Orion Pharma
ClinicalTrials.gov Identifier: NCT01386996     History of Changes
Other Study ID Numbers: 3103004
First Posted: July 1, 2011    Key Record Dates
Last Update Posted: December 22, 2011
Last Verified: December 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Budesonide
Formoterol Fumarate
Budesonide, Formoterol Fumarate Drug Combination
Charcoal
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidotes
Protective Agents